These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
521 related articles for article (PubMed ID: 21262992)
1. Clinical events as a function of proton pump inhibitor use, clopidogrel use, and cytochrome P450 2C19 genotype in a large nationwide cohort of acute myocardial infarction: results from the French Registry of Acute ST-Elevation and Non-ST-Elevation Myocardial Infarction (FAST-MI) registry. Simon T; Steg PG; Gilard M; Blanchard D; Bonello L; Hanssen M; Lardoux H; Coste P; Lefèvre T; Drouet E; Mulak G; Bataille V; Ferrières J; Verstuyft C; Danchin N Circulation; 2011 Feb; 123(5):474-82. PubMed ID: 21262992 [TBL] [Abstract][Full Text] [Related]
2. Letter by Hnid and Chtioui regarding article, "Clinical events as a function of proton pump inhibitor use, clopidogrel use, and cytochrome P450 2C19 genotype in a large nationwide cohort of acute myocardial infarction: results from the French Registry of Acute ST-Elevation and Non-ST-Elevation Myocardial Infarction (FAST-MI) Registry". Hnid K; Chtioui M Circulation; 2011 Sep; 124(11):e297. PubMed ID: 21911791 [No Abstract] [Full Text] [Related]
3. Impact of Proton Pump Inhibitor Use on the Comparative Effectiveness and Safety of Prasugrel Versus Clopidogrel: Insights From the Treatment With Adenosine Diphosphate Receptor Inhibitors: Longitudinal Assessment of Treatment Patterns and Events After Acute Coronary Syndrome (TRANSLATE-ACS) Study. Jackson LR; Peterson ED; McCoy LA; Ju C; Zettler M; Baker BA; Messenger JC; Faries DE; Effron MB; Cohen DJ; Wang TY J Am Heart Assoc; 2016 Oct; 5(10):. PubMed ID: 27792656 [TBL] [Abstract][Full Text] [Related]
4. Genetic determinants of response to clopidogrel and cardiovascular events. Simon T; Verstuyft C; Mary-Krause M; Quteineh L; Drouet E; Méneveau N; Steg PG; Ferrières J; Danchin N; Becquemont L; N Engl J Med; 2009 Jan; 360(4):363-75. PubMed ID: 19106083 [TBL] [Abstract][Full Text] [Related]
5. Impact of the proton pump inhibitors and CYP2C19*2 polymorphism on platelet response to clopidogrel as assessed by four platelet function assays. Tsantes AE; Ikonomidis I; Papadakis I; Bonovas S; Gialeraki A; Kottaridi C; Kyriakou E; Kokori S; Douramani P; Kopterides P; Karakitsos P; Lekakis J; Kapsimali V Thromb Res; 2013 Aug; 132(2):e105-11. PubMed ID: 23830212 [TBL] [Abstract][Full Text] [Related]
6. Impact of proton pump inhibitor therapy on the efficacy of clopidogrel in the CAPRIE and CREDO trials. Dunn SP; Steinhubl SR; Bauer D; Charnigo RJ; Berger PB; Topol EJ J Am Heart Assoc; 2013 Jan; 2(1):e004564. PubMed ID: 23525436 [TBL] [Abstract][Full Text] [Related]
7. Histamine2-receptor antagonists are an alternative to proton pump inhibitor in patients receiving clopidogrel. Wu CY; Chan FK; Wu MS; Kuo KN; Wang CB; Tsao CR; Lin JT Gastroenterology; 2010 Oct; 139(4):1165-71. PubMed ID: 20600012 [TBL] [Abstract][Full Text] [Related]
8. Concomitant Use of Proton Pump Inhibitors and Clopidogrel Is Not Associated with Adverse Outcomes after Ischemic Stroke in Chinese Population. Yi X; Zhou Q; Wang C; Lin J; Cheng W; Chi L J Stroke Cerebrovasc Dis; 2016 Dec; 25(12):2859-2867. PubMed ID: 27546731 [TBL] [Abstract][Full Text] [Related]
9. Cytochrome CYP2C19 polymorphism and risk of adverse clinical events in clopidogrel-treated patients: a meta-analysis based on 23,035 subjects. Mao L; Jian C; Changzhi L; Dan H; Suihua H; Wenyi T; Wei W Arch Cardiovasc Dis; 2013 Oct; 106(10):517-27. PubMed ID: 24080325 [TBL] [Abstract][Full Text] [Related]
10. Correlates of pre-hospital morphine use in ST-elevation myocardial infarction patients and its association with in-hospital outcomes and long-term mortality: the FAST-MI (French Registry of Acute ST-elevation and non-ST-elevation Myocardial Infarction) programme. Puymirat E; Lamhaut L; Bonnet N; Aissaoui N; Henry P; Cayla G; Cattan S; Steg G; Mock L; Ducrocq G; Goldstein P; Schiele F; Bonnefoy-Cudraz E; Simon T; Danchin N Eur Heart J; 2016 Apr; 37(13):1063-71. PubMed ID: 26578201 [TBL] [Abstract][Full Text] [Related]
11. Cytochrome P450 2C19 polymorphism in young patients treated with clopidogrel after myocardial infarction: a cohort study. Collet JP; Hulot JS; Pena A; Villard E; Esteve JB; Silvain J; Payot L; Brugier D; Cayla G; Beygui F; Bensimon G; Funck-Brentano C; Montalescot G Lancet; 2009 Jan; 373(9660):309-17. PubMed ID: 19108880 [TBL] [Abstract][Full Text] [Related]
12. Review article: combination of clopidogrel and proton pump inhibitors: implications for clinicians. Tran M; Tafreshi J; Pai RG J Cardiovasc Pharmacol Ther; 2010 Dec; 15(4):326-37. PubMed ID: 20938037 [TBL] [Abstract][Full Text] [Related]
13. CYP2C19 but not PON1 genetic variants influence clopidogrel pharmacokinetics, pharmacodynamics, and clinical efficacy in post-myocardial infarction patients. Hulot JS; Collet JP; Cayla G; Silvain J; Allanic F; Bellemain-Appaix A; Scott SA; Montalescot G Circ Cardiovasc Interv; 2011 Oct; 4(5):422-8. PubMed ID: 21972404 [TBL] [Abstract][Full Text] [Related]
14. Effect of individual proton pump inhibitors on cardiovascular events in patients treated with clopidogrel following coronary stenting: results from the Ibaraki Cardiac Assessment Study Registry. Aihara H; Sato A; Takeyasu N; Nishina H; Hoshi T; Akiyama D; Kakefuda Y; Watabe H; Aonuma K; Catheter Cardiovasc Interv; 2012 Oct; 80(4):556-63. PubMed ID: 22234956 [TBL] [Abstract][Full Text] [Related]
15. Proton-pump inhibitors are associated with increased cardiovascular risk independent of clopidogrel use: a nationwide cohort study. Charlot M; Ahlehoff O; Norgaard ML; Jørgensen CH; Sørensen R; Abildstrøm SZ; Hansen PR; Madsen JK; Køber L; Torp-Pedersen C; Gislason G Ann Intern Med; 2010 Sep; 153(6):378-86. PubMed ID: 20855802 [TBL] [Abstract][Full Text] [Related]
16. Concomitant proton-pump inhibitor use, platelet activity, and clinical outcomes in patients with acute coronary syndromes treated with prasugrel versus clopidogrel and managed without revascularization: insights from the Targeted Platelet Inhibition to Clarify the Optimal Strategy to Medically Manage Acute Coronary Syndromes trial. Nicolau JC; Bhatt DL; Roe MT; Lokhnygina Y; Neely B; Corbalán R; Leiva-Pons JL; Martinez F; Goodman SG; Winters KJ; Verheugt FW; Armstrong PW; White HD; Fox KA; Prabhakaran D; Ohman EM; Am Heart J; 2015 Oct; 170(4):683-694.e3. PubMed ID: 26386792 [TBL] [Abstract][Full Text] [Related]
17. Association of proton pump inhibitor use on cardiovascular outcomes with clopidogrel and ticagrelor: insights from the platelet inhibition and patient outcomes trial. Goodman SG; Clare R; Pieper KS; Nicolau JC; Storey RF; Cantor WJ; Mahaffey KW; Angiolillo DJ; Husted S; Cannon CP; James SK; Kilhamn J; Steg PG; Harrington RA; Wallentin L; Circulation; 2012 Feb; 125(8):978-86. PubMed ID: 22261200 [TBL] [Abstract][Full Text] [Related]
18. CYP2C19 poor metabolizer is associated with clinical outcome of clopidogrel therapy in acute myocardial infarction but not stable angina. Kim HS; Chang K; Koh YS; Park MW; Choi YS; Park CS; Oh M; Kim EY; Shon JH; Shin JG; Seung KB Circ Cardiovasc Genet; 2013 Oct; 6(5):514-21. PubMed ID: 24019397 [TBL] [Abstract][Full Text] [Related]
19. Prasugrel vs. clopidogrel for cytochrome P450 2C19-genotyped subgroups: integration of the TRITON-TIMI 38 trial data. Sorich MJ; Vitry A; Ward MB; Horowitz JD; McKinnon RA J Thromb Haemost; 2010 Aug; 8(8):1678-84. PubMed ID: 20492467 [TBL] [Abstract][Full Text] [Related]
20. Clopidogrel and proton pump inhibitors--where do we stand in 2012? Drepper MD; Spahr L; Frossard JL World J Gastroenterol; 2012 May; 18(18):2161-71. PubMed ID: 22611308 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]